Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 8;61(5):2104-2110.
doi: 10.1021/acs.jmedchem.7b01605. Epub 2018 Feb 21.

Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening

Samuel H Myers  1 , Carolin Temps  1 , Douglas R Houston  2 , Valerie G Brunton  1 , Asier Unciti-Broceta  1
Affiliations

Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening

Samuel H Myers et al. J Med Chem. .

Abstract

Pyrazolopyrimidines with potent antiproliferative properties were developed by an adaptive strategy that applies ligand-based design and phenotypic screening iteratively and is informed by biochemical assays. To drive development toward specific oncopathways, compounds were tested against cancer cells that overexpress, or not, AXL kinase. Identified phenotypic hits were found to inhibit oncotargets AXL, RET, and FLT3. Subsequent optimization generated antiproliferative lead compounds with unique selectivity profiles, including selective AXL inhibitors and a highly potent inhibitor of FLT3.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Medicinal chemistry campaign based on the cocrystal structure of 52 and MER (PDB 2G15(15)) performed by Wang and co-workers for the discovery of MER inhibitor UNC569 and the 6-methylaminopyrazolo[3,4-d]pyrimidine scaffold explored in this work.
Scheme 1
Scheme 1. Four-Step Synthetic Route for the Preparation of Compounds 7a–j from Commercially Available 6-Chloro-1H-pyrazolo[3,4-d]pyrimidine, 3
Figure 2
Figure 2
EC50 values of 7a–j and the positive control foretinib against AXL– (red) and AXL+ (blue) cells. Cell viability assay: PrestoBlue reagent at day 5. Error bars: ±SD from n = 2.
Scheme 2
Scheme 2. Synthetic Route for the Preparation of Triazole-Containing Compounds 10a–g from Intermediate 5
Figure 3
Figure 3
EC50 values of 10a–g and reference hit 7f against AXL– (red) and AXL+ (blue) cells. Cell viability assay: PrestoBlue reagent at day 5. Error bars: ±SD from n = 2.
Figure 4
Figure 4
Structure, molecular weight (MW), and cLogP of derivatives 12a–f.
Figure 5
Figure 5
EC50 values of 12a–f and reference hit 10a against AXL– (red) and AXL+ (blue) cells. Cell viability assay: PrestoBlue reagent at day 5. Error bars: ±SD from n = 2.
Figure 6
Figure 6
Structure, MW, and cLogP of derivatives 13a–d.
Figure 7
Figure 7
EC50 values of 13a–d and BGB324 against MV4-11 and MOLM-13 cells. Cell viability assay: PrestoBlue reagent at day 5. Error bars: ±SD from n = 2.
Figure 8
Figure 8
Map of the human kinome screened for 13a at 1 μM. Green circles denote <65% inhibition. Red circles denote >65% inhibition (>98% for the largest one).
See this image and copyright information in PMC

References

    1. Avorn J. The $2.6 Billion pill — methodologic and policy considerations. N. Engl. J. Med. 2015, 372, 1877–1879. 10.1056/NEJMp1500848. - DOI - PubMed
    1. DiMasi J. A.; Grabowski H. G.; Hansen R. W. Innovation in the pharmaceutical industry: New estimates of R&D costs. J. Health. Econ. 2016, 47, 20–33. 10.1016/j.jhealeco.2016.01.012. - DOI - PubMed
    1. Kola I.; Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discovery 2004, 3, 711–716. 10.1038/nrd1470. - DOI - PubMed
    1. Lee J. A.; Uhlik M. T.; Moxham C. M.; Tomandl D.; Sall D. J. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J. Med. Chem. 2012, 55, 4527–4538. 10.1021/jm201649s. - DOI - PubMed
    1. Knight Z.; Lin H.; Shokat K. M. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 2010, 10, 130–137. 10.1038/nrc2787. - DOI - PMC - PubMed

Publication types

MeSH terms